{"title":"Undenatured type II collagen for knee osteoarthritis.","authors":"Ashim Gupta, Nicola Maffulli","doi":"10.1080/07853890.2025.2493306","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Knee Osteoarthritis (OA) leads to significant pain and reduced function and affects patients' overall quality of life (QoL). Conservative modalities are the first line of management, resorting to surgery only if they fail. However, these modalities have limitations, and do not address the underlying cause of knee OA. The use of nutraceuticals, including native/undenatured type II collagen (UC-2), has evolved and shown promise in the conservative management of knee OA. This article highlights the mechanism of action, and qualitatively presents the pre-clinical, clinical and on-going scientific literature exploring the safety and efficacy of UC-2 for the management of knee OA.</p><p><strong>Methods: </strong>A search was performed using multiple databases (PubMed, Web of Science, Embase and Scopus) employing terms for UC-2 and Knee OA for articles published in English language, while adhering to Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. All pre-clinical and clinical studies utilizing UC-2 for knee OA were included. Studies not using UC-2 alone or not focusing on the management of knee OA were excluded.</p><p><strong>Results: </strong>Twelve studies (3 pre-clinical studies, 8 clinical studies and 1 study with both pre-clinical and clinical component) met our pre-defined search and inclusion criteria, and were included in this review.</p><p><strong>Discussion: </strong>UC-2 acts <i>via</i> a specific immune mediated mechanism, known as oral tolerance, which can lead to reduced inflammation and enhanced cartilage repair in the knee joint. In addition, administration of UC-2 (40 mg daily) is safe and efficacious in the short- and mid-term, reducing inflammation and pain, and improving function, range of motion (ROM) and overall QoL. Nonetheless, more adequately powered, prospective, multi-center, non-randomized and randomized controlled trials with longer follow-up are warranted to establish the long-term efficacy of UC-2 in knee OA patients and justify its routine clinical use.</p>","PeriodicalId":93874,"journal":{"name":"Annals of medicine","volume":"57 1","pages":"2493306"},"PeriodicalIF":0.0000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12010644/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/07853890.2025.2493306","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/20 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Knee Osteoarthritis (OA) leads to significant pain and reduced function and affects patients' overall quality of life (QoL). Conservative modalities are the first line of management, resorting to surgery only if they fail. However, these modalities have limitations, and do not address the underlying cause of knee OA. The use of nutraceuticals, including native/undenatured type II collagen (UC-2), has evolved and shown promise in the conservative management of knee OA. This article highlights the mechanism of action, and qualitatively presents the pre-clinical, clinical and on-going scientific literature exploring the safety and efficacy of UC-2 for the management of knee OA.
Methods: A search was performed using multiple databases (PubMed, Web of Science, Embase and Scopus) employing terms for UC-2 and Knee OA for articles published in English language, while adhering to Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. All pre-clinical and clinical studies utilizing UC-2 for knee OA were included. Studies not using UC-2 alone or not focusing on the management of knee OA were excluded.
Results: Twelve studies (3 pre-clinical studies, 8 clinical studies and 1 study with both pre-clinical and clinical component) met our pre-defined search and inclusion criteria, and were included in this review.
Discussion: UC-2 acts via a specific immune mediated mechanism, known as oral tolerance, which can lead to reduced inflammation and enhanced cartilage repair in the knee joint. In addition, administration of UC-2 (40 mg daily) is safe and efficacious in the short- and mid-term, reducing inflammation and pain, and improving function, range of motion (ROM) and overall QoL. Nonetheless, more adequately powered, prospective, multi-center, non-randomized and randomized controlled trials with longer follow-up are warranted to establish the long-term efficacy of UC-2 in knee OA patients and justify its routine clinical use.
膝关节骨关节炎(OA)会导致明显的疼痛和功能下降,并影响患者的整体生活质量(QoL)。保守疗法是治疗的第一线,只有在治疗失败时才诉诸于手术。然而,这些方式有局限性,并不能解决膝关节炎的根本原因。包括天然/未变性II型胶原蛋白(UC-2)在内的营养保健品的使用在膝关节OA的保守治疗中不断发展并显示出前景。本文重点介绍了UC-2的作用机制,并定性地介绍了临床前、临床和正在进行的科学文献,探讨了UC-2治疗膝关节OA的安全性和有效性。方法:使用多个数据库(PubMed, Web of Science, Embase和Scopus)进行搜索,使用UC-2和膝关节OA的术语发表在英语语言的文章,同时遵循系统评价和荟萃分析(PRISMA)指南的首选报告项目。所有使用UC-2治疗膝关节OA的临床前和临床研究均被纳入。不单独使用UC-2或不关注膝关节OA治疗的研究被排除在外。结果:12项研究(3项临床前研究,8项临床研究和1项临床前和临床研究同时进行的研究)符合我们预先定义的检索和纳入标准,并被纳入本综述。讨论:UC-2通过一种被称为口服耐受的特定免疫介导机制起作用,可导致膝关节炎症减少和软骨修复增强。此外,UC-2(每日40 mg)短期和中期安全有效,可减轻炎症和疼痛,改善功能,活动范围(ROM)和总体生活质量。尽管如此,需要更充分的、前瞻性的、多中心的、非随机的和随机的、随访时间较长的对照试验来确定UC-2在膝关节OA患者中的长期疗效,并证明其常规临床应用的合理性。